Skye Bioscience is a biopharmaceutical company focused on developing innovative therapeutic solutions for obesity and metabolic diseases. Their primary technology revolves around the inhibition of the peripheral CB1 receptor, which is a validated mechanism that complements existing weight loss therapies. This approach aims to enhance metabolic processes, such as increasing energy expenditure and improving leptin sensitivity, which can lead to more effective and sustainable weight loss outcomes. Skye's lead drug candidate, nimacimab, is a first-in-class monoclonal antibody that acts as a negative allosteric modulator of the CB1 receptor. It has shown a positive safety profile in Phase 1 trials and offers the potential for less frequent dosing, which could improve patient adherence to treatment.

The company is committed to advancing its drug candidates through rigorous drug design, manufacturing, and clinical development processes. Skye's current focus is on the CB1 receptor, with ongoing clinical trials, including the CBeyond™ Phase 2 study for nimacimab, which began in August 2024. The company aims to address significant unmet medical needs in the obesity market by providing differentiated therapeutic mechanisms that can lead to improved health outcomes for patients suffering from obesity and related metabolic conditions. Skye Bioscience emphasizes high-quality science and collaboration in its mission to develop transformative therapies for these prevalent health issues.

United States

Skye Bioscience, Inc. is a pharmaceutical company focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially with a focus on modulating the system for the treatment of glaucoma and other diseases. They are developing proprietary cannabinoid derivatives for therapeutic use.

Skye Bioscience

Company Details